Search the GHTC website

Global health R&D delivers for Missouri

US government investment in global health R&D has delivered

$344.4 million
to Missouri research institutions
4,100+ new jobs
for Missouri
Missouri's top USG-funded global health R&D institutions

Missouri's top USG-funded global health R&D institutions

Washington University in St Louis
$254 million
Saint Louis University
$45.7 million
MRIGlobal (formerly Midwest Research Institute)
$19.3 million
University of Missouri-Columbia
$8 million
University of Missouri-Kansas City
$4.8 million
Missouri Department of Health and Senior Services
$4.1 million
Omniose (formerly VaxNewMo)
$3.1 million
University of Health Sciences and Pharmacy in St. Louis
$2.4 million
Fimbrion Therapeutics
$1.7 million
Divergence Inc.*
$403 thousand
Mediomics LLC
$358 thousand
Precision Virologics
$343 thousand
University of Missouri-St. Louis
$100 thousand
$81 thousand

Missouri's top areas of global health R&D by USG funding

Other coronaviruses (including MERS, SARS)
Diarrheal diseases
Flioviral diseases (including Ebola, Marburg)
Neglected tropical diseases
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
Reproductive health
Salmonella infections
Bacterial pneumonia & meningitis
Bunyaviral diseases (including CCHF, RVF, SFTS)
Cryptococcal meningitis
Emergent non-polio enteroviruses (including EV71, D68)
Henipaviral diseases (including Nipah)
Hepatitis B
Hepatitis C
Multi-disease/health area R&D
Global health R&D at work in Missouri

Researchers at the Washington University School of Medicine are working to develop a pan-coronavirus vaccine that protects against multiple coronaviruses. The research team is focused on the subgroup of coronaviruses, called betacoronviruses, to which SARS, MERS, and COVID-19 belong. Their goal is to produce a vaccine capable of reducing sickness and death in the event of an outbreak of a known or unknown betacoronavirus—slowing the spread of the disease and buying scientists more time to develop a vaccine targeted to the specific virus. The same research team also helped develop a nasal-administered COVID-19 vaccine that is now approved in India. The vaccine was licensed to a US-based biotech with the intent to advance its potential approval in the United States.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: USAID/Alex Kamweru